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Abstract
Purpose—In 2009, the US Food and Drug Administration (FDA) mandated a label change for 
leukotriene inhibitors (LTIs) to include neuropsychiatric adverse events (eg, depression and 
suicidality) as a precaution. This study investigated how this label change affected the use of LTIs 
and other asthma controller medications, mental health visits, and suicide attempts.
Methods—We analyzed data (2005–2010) from 5 large health plans in the US Population-Based 
Effectiveness in Asthma and Lung Diseases (PEAL) Network. The study cohort included children 
and adolescents (n = 30,000), young adults (n = 20,000), and adults (n = 90,000) with asthma. We 
used interrupted time series to examine changes in rates of LTI dispensings, non-LTI dispensings, 
mental health visits, and suicide attempts (using a validated algorithm based on a combination of 
diagnoses of injury or poisoning and psychiatric conditions).
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Findings—The label change was associated with abrupt reductions in LTI use among all age 
groups (relative reductions of 8.3%, 15.1%, and 6.0% among adolescents, young adults, and 
adults, respectively, compared with expected rates at 1 year after the warnings). Although we 
detected immediate offset increases in non-LTI asthma medication use, these increases were not 
sustained among adolescents and young adults. There were small increases in mental health visits 
among LTI users.
Implications—The FDA label change for LTIs communicated possible risk of neuropsychiatric 
events. Communication and enhanced awareness may have increased reporting of mental health 
symptoms among young adults and adults. It is important to assess intended and unintended 
consequences of FDA warnings and label changes.
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INTRODUCTION
During the last decade, there has been increasing recognition of the potential for certain 
prescription medications to increase the risk of psychiatric symptoms and suicidality.1 
Primarily on the basis of spontaneous adverse drug event reports (eg, via the MedWatch 
system), the US Food and Drug Administration (FDA) has issued communications and 
warnings about psychiatric symptoms and suicidality for whole classes of medications. 
These warnings initially included selective serotonin receptor inhibitors and were later 
expanded to all antidepressants, antiepileptic drugs, the smoking-cessation drug varenicline,2 
and leukotriene inhibitors (LTIs).
LTIs include montelukast, zafirlukast, and zileuton in the United States and are the second 
most commonly used controller medications for asthma after inhaled corticosteroids. LTIs 
are also used for seasonal allergies. The FDA first issued alerts in March 20083 and 
reviewed postmarketing reports of patients taking LTIs and clinical trial data submitted by 
manufacturers. Most reported neuropsychiatric adverse events were associated with 
montelukast. Although these data do not suggest that LTIs are associated with suicidality, 
these clinical trials were not designed specifically to examine neuropsychiatric events.
In June 2009, the FDA required manufacturers of LTIs to include neuropsychiatric adverse 
events as a precaution on the drug label.4 In the risk communications, the FDA 
recommended that “patients and prescribers should monitor for the possibility of 
neuropsychiatric events associated with these agents.”3 Neuropsychiatric events include 
agitation, aggression, anxiety, sleep disorder, depression, and suicidal thinking and behavior 
(including suicide and suicide attempts).4 The widespread use of LTIs heightened the 
concern about the potential association with suicide. At the same time, excessive caution 
could mean that effective therapies are withheld from patients who could benefit from them. 
The aims of this study were to examine the effects of the FDA label change for LTIs on 
patterns of treatment for asthma, mental health visits, and suicide attempts.
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METHODS
Data Sources
This study included individuals with asthma in the Population-Based Effectiveness in 
Asthma and Lung Diseases (PEAL) Network.5–7 Five health plans from this network 
participated in this study: Harvard Pilgrim Health Care, HealthPartners, Kaiser Permanente 
Northern California, Kaiser Permanente Georgia, and Kaiser Permanente Northwest. 
Electronic data from subjects from each of the 5 sites were pooled to form the PEAL Data 
Warehouse, which includes information on demographic characteristics, health plan 
enrollment, dispensings of medications, and use of inpatient and outpatient health care 
services. The institutional review board at each site approved this study.
Study Design and Cohorts
Randomized controlled trials are not able to evaluate nationwide policy changes such as 
FDA warnings. We used an interrupted times series design,8–12 which can provide strong 
evidence of causal effects because it controls for prepolicy secular trends in study outcomes. 
The approach measures whether a policy causes abrupt changes in the level and/or the 
preexisting trend (slope) of study outcomes.8–12 To calculate population-level time series, 
we created a rolling cohort from January 2005 through December 2010. For every month, 
we identified and included health plan members who had (1) continuous enrollment for the 
past 12 months, (2) continuous enrollment for the current month, (3) at least one outpatient 
or inpatient visit in the past 12 months with a diagnosis of asthma (International 
Classification of Diseases, Ninth Revision (ICD-9) code for asthma [493.x]), and (4) no 
history of chronic obstructive pulmonary diseases (ICD-9 codes 491, 492, and 496); cystic 
fibrosis (ICD-9 code 277.0x); bronchiectasis (ICD-9 code 494); pulmonary hypertension or 
embolism (ICD-9 codes 416.0 and 415.1); bronchopulmonary dysplasia (ICD-9 code 770.7); 
or congestive heart failure (ICD-9 code 428) in the past 12 months. We excluded subjects 
with these comorbid illnesses, as we have done in previous studies,13,14 because asthma 
medications can be used for these chronic illnesses, which are distinct from asthma. These 
criteria were consistent with recent studies of FDA warnings among the asthma population 
using similar data.15 We included children and adolescents (ages 5–17 years), young adults 
(ages 18–29 years), and adults (ages 30–64 years) because the prevalence of suicidality is 
higher among young adults aged 18 through 29 years than among adults 30 years and older 
based on the US Centers for Disease Control and Prevention data.16 In addition, we 
identified users of LTIs; for each month, we identified and included individuals who had a 
dispensing for a LTI agent in the previous 6 months and met the above study criteria.
Outcome Measures
Among the rolling cohorts of asthmatic patients, we calculated the monthly percentage of 
individuals dispensed an LTI, dispensed a non-LTI medication, or who had a mental health 
visit. We also calculated the quarterly percentage of patients who were medically treated for 
suicide attempt. To construct these measures, for each month, we identified individuals with 
asthma who (1) were dispensed an LTI medication, (2) were dispensed a non-LTI asthma 
controller medication (inhaled corticosteroids and inhaled corticosteroids with long-acting 
β-agonists), and (3) who had a mental health visit (defined using Current Procedural 
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Terminology psychiatric codes [908xx series] and ICD-9 codes [290– 314]17). For each 
quarter, we identified asthmatic patients hospitalized or treated in the emergency department 
for suicide attempts using a validated algorithm18 based on a combination of diagnoses of 
injury or poisoning and psychiatric conditions; this algorithm has a positive predictive value 
of 87.8% for suicide attempts.18 Although encounters for suicide attempts can be identified 
in administrative databases using external cause of injury codes (E-codes), they are known to 
be incompletely captured in commercial plan databases19; thus, we used a previously 
validated algorithm.18
Statistical Analysis
We used segmented regression models8 to estimate cohort-level changes in our outcome 
measures from the prelabel change period (January 1, 2005, to June 30, 2009) to the 
postlabel change period (July 1, 2009, to December 31, 2010). We analyzed each age group 
separately and adjusted for baseline (control) trends and for seasonal trends in statistical 
models. The models included a binary indicator to estimate the immediate-level change in 
outcome measures and a term to estimate the trend change. We also estimated absolute and 
relative differences (with 95% CIs)20 in observed versus predicted rates at 1-year postlabel 
change (ie, in June 2010) to represent the full effect of the label change. For parsimony, we 
excluded nonsignificant (P ≥ 0.20) time-series terms in a reverse stepwise fashion; exclusion 
of nonsignificant terms did not meaningfully change the coefficients on the remaining 
terms.8 We controlled for significant autocorrelation terms in the models. We conducted all 
statistical analyses using SAS statistical software, version 9.3 (SAS Institute, Cary, North 
Carolina).
RESULTS
The rolling cohorts included approximately 30,000 children and adolescents, 20,000 young 
adults, and 90,000 adults per month with asthma; the key characteristics were stable over 
time (Table I). Table II presents estimated changes in levels and trends in study outcomes 
from segmented regression models. Table III provides absolute and relative changes in study 
outcomes at 1 year after the label change.
Effects of the Label Change Among Children and Adolescents
Immediately before the label change, 2.79% of children and adolescents used LTIs, 5.77% 
used non-LTI asthma controller medications, 7.69% of LTI users had mental health visits, 
and 0.05% were medically treated for suicide attempts. After the label change, there was a 
small shift in use from LTIs to non-LTI asthma medications (Figure 1A), with LTI use 
decreasing 0.23 percentage points (95% CI, −0.44 to −0.01) and non-LTI use increasing 0.54 
percentage points (95% CI, 0.20–0.89; Table II). These changes led to a relative reduction of 
8.31% in LTI use (95% CI, −15.92 to −0.71; Table III) without significant offset increases in 
non-LTI medication use at 1 year after the label change. Immediately after the label change, 
mental health visits increased 0.25 percentage points (95% CI, 0.01–0.49; Figure 1B) among 
LTI users, leading to a relative increase of 3.56% (95% CI, 0.10–7.01). We did not observe 
changes in suicide attempts (Figure 1C).
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Effects of the Label Change Among Young Adults
Immediately before the label change, approximately 1.68% of young adults used LTIs, 
5.81% used non-LTI asthma controller medications, 7.94% of LTI users had mental health 
visits, and 0.06% were medically treated for suicide attempts. After the label change, there 
was a small shift in use from LTIs to non-LTI asthma medications (Figure 2A). The label 
change was associated with a small decrease of 0.02 percentage points per month in the 
trend of LTIs (95% CI, −0.03 to −0.01; Table II). This reduction was offset by increases in 
non-LTI medication use, with an immediate increase of 0.46 percentage points (95% CI, 
0.14–0.79), although this increase was not sustained because there was a reduction of 0.04 
percentage points per month (95% CI, −0.06 to −0.01). These changes led to a relative 
reduction of 15.1% in LTI use (95% CI, −22.89 to −7.25; Table III) without apparent offset 
increases in non-LTI medication use at 1 year after the label change. We did not detect 
changes in mental health visits among LTI users (Figure 2B). Immediately after the label 
change, there was a small increase of 0.03 percentage points (95% CI, 0.01–0.05) in suicide 
attempts (Figure 2C).
Effects of the Label Change Among Adults
Immediately before the label change, approximately 2.72% of adults used LTIs, 10.53% 
used non-LTI asthma controller medications, 8.32% of LTI users had mental health visits, 
and 0.03% were medically treated for suicide attempts. After the label change, there was a 
small shift in use from LTIs to non-LTI asthma medications (Figure 3A). The label change 
was associated with a small decrease of 0.01 percentage points per month in the trend of 
LTIs (95% CI, −0.02 to −0.004; Table II). This reduction was offset by an immediate 
increase of 0.44 percentage points (95% CI, 0.03–0.84) in use of non-LTI asthma 
medications. These changes led to a relative reduction of 6.00% in LTI use (95% CI, −10.34 
to −1.66; Table III) that was offset by a relative increase of 4.59% in non-LTI medication use 
(95% CI, 0.27–8.92) at 1 year after the label change. Immediately after the label change, 
mental health visits increased 0.61 percentage points (95% CI, 0.30–0.91; Figure 3B) among 
LTI users, leading to a relative increase of 8.16% (95% CI, 3.91–12.40). After the label 
change, there was a small increase of 0.002 percentage points per month (95% CI, 0.001–
0.003) in suicide attempts (Figure 3C).
DISCUSSION
Our study of treatment patterns among a large and geographically diverse population of 
patients with asthma revealed small effects associated with the 2009 FDA label change for 
LTIs. After the label change, there were small reductions in LTI use among all age groups. 
Our study also assessed the extent of substitution with alternative treatments. Although we 
detected immediate offset increases in non-LTI medication use, there were no increases in 
trend. Among adolescents and adults, there were small increases in mental health visits for 
LTI users after the label change. There were some apparent small increases in suicide 
attempts, measured by a proxy based on diagnoses of injury or poisoning and psychiatric 
conditions, among young adults and adults. The observed small increases in mental health 
visits and suicide attempts may be explained by increased reporting of mental health 
symptoms.
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The lack of substantial changes after the FDA label change for LTIs is not surprising. First, 
to date, there is no definitive evidence of an association between LTIs and suicide based on 
FDA’s review of adverse event data from manufacturer-conducted placebo-controlled 
clinical trials4 or observational studies.21,22 In the case of LTIs, the intent of the label change 
was to provide clinicians and patients with updated information necessary to make rational 
treatment decisions. Minimal changes in LTI use and mental health visits are likely 
appropriate responses. Second, the FDA only required labeling changes to communicate the 
risk of neuropsychiatric events associated with LTIs. The type of FDA communications used 
may influence the level of public awareness and the extent of change in prescriber behavior. 
These communications range from minor revisions to the label of the drug to boxed 
warnings when risks are particularly severe; boxed warnings are FDA’s strongest warning 
given to a drug or drug class.
Lay media can play an important role in changing medication use and health outcomes 
because messages in FDA drug risk communications may be oversimplified and distorted 
through media channels.23 Furthermore, the publicity itself may affect the response to FDA 
label changes and warnings.24,25 We previously found that the widely publicized FDA 
warnings for antidepressants and suicidality led to substantial reductions in antidepressant 
use and simultaneous increases in suicide attempts by poisonings among youth,12 suggesting 
that excessive caution might have resulted in reduced use of effective therapies for patients 
who could benefit from them. Compared with antidepressants, the safety concern about LTIs 
and FDA label change received little media attention; thus, there were no substantial changes 
after the FDA warnings.
Strengths of this study include the large number of individuals from across the country 
studied over a longitudinal period of 6 years. Furthermore, this is the first study to 
investigate changes in use of LTIs and other asthma controller medications, mental health 
visits, and suicide attempts after an FDA-mandated label change for LTIs. The FDA has 
moved toward broader and more proactive communication of drug warnings for marketed 
drugs in recent years. Risk communications can have intended and unintended effects, 
making such studies important.24
Several limitations deserve mention. First, our follow-up period was 18 months, so we could 
not observe changes in outcomes beyond this period. Second, our outcomes may not have 
been fully captured because we elected not to use deliberate self-harm E-codes because they 
are incompletely coded across sites participating in this study and in commercial plan 
databases generally.19 Third, our sample comprised insured populations (commercial plans 
and public insurers); the findings may not reflect behavior among uninsured patients. Fourth, 
because suicide attempts are extremely rare, even with our large sample, we could not 
stratify our analysis of suicide attempts by key characteristics, such as sex, socioeconomic 
status, and race/ethnicity, to better understand the impact of FDA’s label change among 
select patient groups. Notwithstanding these limitations, given our study’s interrupted time 
series design,8–12 we provide evidence that the FDA label change led to small, short-term 
reductions in LTI use, but these reductions were not offset by increases in non-LTI asthma 
medication use among adolescents and young adults. Less optimal use of asthma controller 
medications may influence asthma-related adverse outcomes (eg, asthma-related 
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hospitalization). Further studies are needed to examine effects of this label change–induced 
change in asthma controller medication use on asthma-related clinical outcomes.
Because knowledge of the risk of drugs is continually evolving, it is often necessary for the 
FDA and manufacturers to update a product’s label with new information on the safety 
profile. Regulators face the challenge of designing clear risk messages that are maximally 
effective, are specific, and do not become risks themselves. The FDA’s drug risk 
communications exist within a sea of information (including lay media) that may influence 
the behavior of patients and clinicians. Active surveillance is needed to allow timely 
detection of unintended effects of drug risk communications.
CONCLUSIONS
The FDA’s label change for LTIs that communicated the possible risk of neuropsychiatric 
events led to reduced use of LTIs without corresponding increases in non-LTI medication 
use among young people. Further research is warranted to study the impact of reduced 
asthma controller medication use on clinical outcomes. This label change may have also 
increased reporting of mental health symptoms among young adults and adults. Risk 
communications may affect behavior of medication use and related health services. It is 
important to monitor intended and unintended consequences of FDA warnings and label 
changes.
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Figure 1. 
Rates of medication use (A), mental health visits (B), and suicide attempts (C) before and 
after the Food and Drug Administration (FDA) label change among adolescents enrolled in 5 
health plans in the nationwide Population-Based Effectiveness in Asthma and Lung Diseases 
Network. LTI = leukotriene inhibitor.
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Figure 2. 
Rates of medication use (A), mental health visits (B), and suicide attempts (C) before and 
after the Food and Drug Administration (FDA) label change among young adults enrolled in 
5 health plans in the nationwide Population-Based Effectiveness in Asthma and Lung 
Diseases Network. LTI = leukotriene inhibitor.
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Figure 3. 
Rates of medication use (A), mental health visits (B), and suicide attempts (C) before and 
after the Food and Drug Administration (FDA) label change among adults enrolled in 5 
health plans in the nationwide Population-based Effectiveness in Asthma and Lung Diseases 
Network. LTI = leukotriene inhibitor.
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Table II
Parameter estimates, 95% CIs, and P values from the most parsimonious segmented regression models 
predicting monthly percentages of medication use and mental health visits and quarterly percentages of suicide 
attempts by age group.
Parameter Estimate (95% CI) P
Adolescents
  LTI dispensings
    Immediate impact −0.23 (−0.44 to −0.01) 0.0400
    Trend 0
  Non-LTI dispensings
    Immediate impact 0.54 (0.20–0.89) 0.0026
    Trend −0.02 (−0.06 to 0.01) 0.1448
  Asthma drug dispensings
    Immediate impact 0.37 (−0.03 to 0.77) 0.0674
    Trend −0.04 (−0.07 to −0.01) 0.0232
  Mental health visits (LTI users)
    Immediate impact 0.25 (0.01–0.49) 0.0454
    Trend 0
  Suicide attempts
    Immediate impact 0
    Trend 0
Young adults
  LTI dispensings
    Immediate impact −0.02 (−0.03 to −0.01) 0.0013
    Trend 0
  Non-LTI dispensings
    Immediate impact 0.46 (0.14–0.79) 0.0058
    Trend −0.04 (−0.06 to −0.01) 0.0082
  Asthma drug dispensings
    Immediate impact 0.40 (0.07–0.74) 0.0191
    Trend −0.05 (−0.08 to −0.02) 0.0006
  Mental health visits (LTI users)
    Immediate impact 0
    Trend 0
  Suicide attempts
    Immediate impact 0.03 (0.01–0.05) 0.0032
    Trend 0
Adults
  LTI dispensings
    Immediate impact 0
    Trend −0.01 (−0.02 to 0.00) 0.0095
  Non-LTI dispensings
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Parameter Estimate (95% CI) P
    Immediate impact 0.44 (0.03–0.84) 0.0351
    Trend 0
  Asthma drug dispensing
    Immediate impact 0.39 (0.00–0.79) 0.0503
    Trend 0
  Mental health visits (LTI users)
    Immediate impact 0.61 (0.30–0.91) 0.0002
    Trend 0
  Suicide attempts
    Immediate impact 0
    Trend 0.002 (0.001–0.003) 0.001
LTI = leukotriene inhibitor.
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Table III
Absolute and relative changes in medication use, mental health visits, and suicide attempts by 1 year after the 
warnings compared with expected rates derived from baseline trend.
Parameter Absolute Change (95% CI), % Relative Change (95% CI), %
Adolescents
  LTI dispensings −0.23 (−0.44 to −0.01) −8.31 (−15.92 to −0.71)
  Non-LTI dispensings 0.25 (−0.13 to 0.63) 5.11 (−2.83 to 13.05)
  Asthma drug dispensings −0.09 (−0.40 to 0.22) −1.26 (−5.66 to 3.15)
  Mental health visits (LTI users) 0.25 (0.01–0.49) 3.56 (0.10–7.01)
  Suicide attempts 0 0
Young adults
  LTI dispensings −0.26 (−0.41 to −0.11) −15.07 (−22.89 to −7.25)
  Non-LTI dispensings 0.02 (−0.23 to 0.28) 0.47 (−4.59 to 5.54)
  Asthma drug dispensings −0.19 (−0.46 to 0.07) −3.10 (−7.21 to 1.00)
  Mental health visits (LTI users) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
  Suicide attempts 0.03 (0.01–0.05) 66.31 (9.83–122.79)
Adults
  LTI dispensings −0.17 (−0.29 to −0.04) −6.00 (−10.34 to −1.66)
  Non-LTI dispensings 0.44 (0.04–0.83) 4.59 (0.27–8.92)
  Asthma drug dispensings 0.39 (0.01–0.78) 3.49 (−0.03 to 7.00)
  Mental health visits (LTI users) 0.61 (0.31–0.91) 8.16 (3.91–12.40)
  Suicide attempts 0.01 (0.00–0.01) 23.47 (10.95–35.99)
LTI = leukotriene inhibitor.
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